Evidence map›Paper›PMID 38942798›Full record

ArticleNature communications2024

PIKfyve, expressed by CD11c-positive cells, controls tumor immunity.

Jae Eun Choi, Yuanyuan Qiao, Ilona Kryczek, Jiali Yu, Jonathan Gurkan, Yi Bao, Mahnoor Gondal, Jean Ching-Yi Tien, Tomasz Maj, Sahr Yazdani and 18 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

28 authors.

Jae Eun ChoiDepartment of Pathology, University of Michigan, Ann Arbor, MI, USA.
Yuanyuan QiaoDepartment of Pathology, University of Michigan, Ann Arbor, MI, USA.ORCID 0000-0002-1178-3480
Ilona KryczekDepartment of Surgery, University of Michigan, Ann Arbor, MI, USA.ORCID 0000-0002-3130-2533
Jiali YuDepartment of Surgery, University of Michigan, Ann Arbor, MI, USA.
Jonathan GurkanDepartment of Pathology, University of Michigan, Ann Arbor, MI, USA.ORCID 0000-0002-0149-3463
Yi BaoDepartment of Pathology, University of Michigan, Ann Arbor, MI, USA.
Mahnoor GondalDepartment of Pathology, University of Michigan, Ann Arbor, MI, USA.ORCID 0000-0002-9419-6758
Jean Ching-Yi TienDepartment of Pathology, University of Michigan, Ann Arbor, MI, USA.
Tomasz MajDepartment of Surgery, University of Michigan, Ann Arbor, MI, USA.ORCID 0000-0002-8431-1361
Sahr YazdaniDepartment of Pathology, University of Michigan, Ann Arbor, MI, USA.
Abhijit ParoliaDepartment of Pathology, University of Michigan, Ann Arbor, MI, USA.
Houjun XiaDepartment of Surgery, University of Michigan, Ann Arbor, MI, USA.
JiaJia ZhouDepartment of Surgery, University of Michigan, Ann Arbor, MI, USA.
Shuang WeiDepartment of Surgery, University of Michigan, Ann Arbor, MI, USA.
Sara GroveDepartment of Surgery, University of Michigan, Ann Arbor, MI, USA.
Linda VatanDepartment of Surgery, University of Michigan, Ann Arbor, MI, USA.
Heng LinDepartment of Surgery, University of Michigan, Ann Arbor, MI, USA.
Gaopeng LiDepartment of Surgery, University of Michigan, Ann Arbor, MI, USA.
Yang ZhengDepartment of Pathology, University of Michigan, Ann Arbor, MI, USA.ORCID 0000-0002-6793-3206
Yuping ZhangDepartment of Pathology, University of Michigan, Ann Arbor, MI, USA.ORCID 0000-0002-8727-5183
Xuhong CaoDepartment of Pathology, University of Michigan, Ann Arbor, MI, USA.
Fengyun SuDepartment of Pathology, University of Michigan, Ann Arbor, MI, USA.
Rui WangDepartment of Pathology, University of Michigan, Ann Arbor, MI, USA.
Tongchen HeDepartment of Pathology, University of Michigan, Ann Arbor, MI, USA.
Marcin CieslikDepartment of Pathology, University of Michigan, Ann Arbor, MI, USA.
Michael D GreenCenter of Excellence for Cancer Immunology and Immunotherapy, University of Michigan, Ann Arbor, MI, USA.ORCID 0000-0003-4951-7118
Weiping ZouDepartment of Pathology, University of Michigan, Ann Arbor, MI, USA. wzou@umich.edu.ORCID 0000-0001-7952-3549
Arul M ChinnaiyanDepartment of Pathology, University of Michigan, Ann Arbor, MI, USA. arul@umich.edu.ORCID 0000-0001-9282-3415

Funding

Tissue/InformaticsP50CA186786 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Ganesh S Palapattu · 2014 to 2026
$27.6M
Exploring Precision Oncology: From Gene Fusions to lncRNAsR35CA231996 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI CHINNAIYAN, ARUL M · 2018 to 2024
$6.4M
NCI NIH HHS P50 CA186786NCI NIH HHS R35 CA231996U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) F31 CA26461-01
6 · The paper itself

Abstract

Cancer treatment continues to shift from utilizing traditional therapies to targeted ones, such as protein kinase inhibitors and immunotherapy. Mobilizing dendritic cells (DC) and other myeloid cells with antigen presenting and cancer cell killing capacities is an attractive but not fully exploited approach. Here, we show that PIKFYVE is a shared gene target of clinically relevant protein kinase inhibitors and high expression of this gene in DCs is associated with poor patient response to immune checkpoint blockade (ICB) therapy. Genetic and pharmacological studies demonstrate that PIKfyve ablation enhances the function of CD11c

Indexed as

CD11c AntigenDendritic CellsMorpholinesPhosphatidylinositol 3-KinasesAnimalsCell Line, TumorFemaleHumansHydrazonesImmune Checkpoint InhibitorsImmunotherapyMaleMiceMice, Inbred C57BLNeoplasmsNF-kappa BapilimodCD11c AntigenHydrazonesImmune Checkpoint InhibitorsMorpholinesNF-kappa BPhosphatidylinositol 3-KinasesPIKFYVE protein, humanPikfyve protein, mouseProtein Kinase InhibitorsPyrimidines

Identifiers

PMID38942798
PMCPMC11213953

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.